Rogues A M, Dumartin C, Amadéo B, Venier A G, Marty N, Parneix P, Gachie J P
Unité INSERM 657-Pharmacoépidémiologie et évaluation de l'impact des produits de santé sur populations, IFR Santé Publique Université Victor Ségalen, France.
Infect Control Hosp Epidemiol. 2007 Dec;28(12):1389-95. doi: 10.1086/523280. Epub 2007 Nov 1.
To investigate relationships between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from hospitals.
We conducted an observational study that used retrospective data from 2002 and linear regression to model relationships. Hospitals were asked to collect data on consecutive S. aureus and P. aeruginosa isolates, consumption rates for antibiotics (ie, anti-infectives for systemic use as defined by Anatomical Therapeutic Chemical class J01), and hospital characteristics, including infection control policies. Rates of methicillin resistance in S. aureus and rates of ceftazidime and ciprofloxacin resistance in P. aeruginosa were expressed as the percentage of isolates that were nonsusceptible (ie, either resistant or intermediately susceptible) and as the incidence of nonsuceptible isolates (ie, the number of nonsuceptible isolates recovered per 1,000 patient-days). The rate of antimicrobial consumption was expressed as the number of defined daily doses per 1,000 patient-days.
Data were obtained from 47 French hospitals, and a total of 12,188 S. aureus isolates and 6,370 P. aeruginosa isolates were tested.
In the multivariate analysis, fewer antimicrobials showed a significant association between the consumption rate and the percentage of isolates that were resistant than an association between the consumption rate and the incidence of resistance. The overall rate of antibiotic consumption, not including the antibiotics used to treat methicillin-resistant S. aureus infection, explained 13% of the variance between hospitals in the incidence of methicillin resistance among S. aureus isolates. The incidence of methicillin resistance in S. aureus isolates increased with the use of ciprofloxacin and levofloxacin and with the percentage of the hospital's beds located in intensive care units (adjusted multivariate coefficient of determination [aR(2)], 0.30). For P. aeruginosa, the incidence of ceftazidime resistance was greater in hospitals with higher consumption rates for ceftazidime, levofloxacin, and gentamicin (aR(2), 0.37). The incidence of ciprofloxacin resistance increased with the use of fluoroquinolones and with the percentage of a hospital's beds located in intensive care ( aR(2), 0.28).
A statistically significant relationship existed between the rate of fluoroquinolone use and the rate of antimicrobial resistance among S. aureus and P. aeruginosa isolates. The incidence of resistant isolates showed a stronger association with the rate of antimicrobial use than did the percentage of isolates with resistance.
调查医院中金黄色葡萄球菌和铜绿假单胞菌分离株的抗菌药物使用速率与抗菌药物耐药性发生率之间的关系。
我们进行了一项观察性研究,使用2002年的回顾性数据并通过线性回归来建立关系模型。要求医院收集连续的金黄色葡萄球菌和铜绿假单胞菌分离株数据、抗生素使用速率(即解剖治疗化学分类J01定义的全身用抗感染药物)以及医院特征,包括感染控制政策。金黄色葡萄球菌的甲氧西林耐药率以及铜绿假单胞菌的头孢他啶和环丙沙星耐药率以不敏感分离株的百分比(即耐药或中介敏感)以及不敏感分离株的发生率(即每1000个患者日回收的不敏感分离株数量)表示。抗菌药物使用速率以每1000个患者日的限定日剂量数表示。
数据来自47家法国医院,共检测了12188株金黄色葡萄球菌分离株和6370株铜绿假单胞菌分离株。
在多变量分析中,与耐药分离株发生率相比,较少的抗菌药物显示出使用速率与耐药分离株百分比之间存在显著关联。不包括用于治疗耐甲氧西林金黄色葡萄球菌感染的抗生素在内的总体抗生素使用速率,解释了医院间金黄色葡萄球菌分离株中甲氧西林耐药发生率差异的13%。金黄色葡萄球菌分离株的甲氧西林耐药发生率随着环丙沙星和左氧氟沙星的使用以及医院重症监护病房床位的百分比增加而升高(调整后的多变量决定系数[aR(2)],0.30)。对于铜绿假单胞菌,在头孢他啶、左氧氟沙星和庆大霉素使用速率较高的医院中,头孢他啶耐药发生率更高(aR(2),0.37)。环丙沙星耐药发生率随着氟喹诺酮类药物的使用以及医院重症监护床位的百分比增加而升高(aR(2),0.28)。
氟喹诺酮类药物使用速率与金黄色葡萄球菌和铜绿假单胞菌分离株的抗菌药物耐药率之间存在统计学上的显著关系。耐药分离株的发生率与抗菌药物使用速率的关联比耐药分离株的百分比更强。